Antiepileptic treatment with levetiracetam during the first trimester and pregnancy outcome: An observational study

被引:2
|
作者
Hoeltzenbein, Maria
Bartz, Insa
Fietz, Anne-Katrin
Lohse, Lukas
Onken, Marlies
Dathe, Katarina
Schaefer, Christof
机构
[1] Charite Univ Med Berlin, Embryotox Ctr Clin Teratol & Drug Safety Pregnanc, Inst Clin Pharmacol & Toxicol, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
关键词
birth defects; epilepsy; levetiracetam; pregnancy outcome; spontaneous abortion; PERINATAL SURVEY DATA; ANTHROPOMETRIC DIMENSIONS; PERCENTILE VALUES; NEONATES ANALYSIS; FETAL-GROWTH; 16; STATES; DRUGS; EPILEPSY; MALFORMATIONS; COHORT;
D O I
10.1111/epi.17800
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveLevetiracetam is increasingly used in pregnant women with epilepsy. Although teratogenic effects have not been observed so far, data on the risks of spontaneous abortion and major birth defects are still limited, especially for the frequently used dual therapy of levetiracetam and lamotrigine. Our primary aim was to analyze rates of major birth defects and spontaneous abortion after maternal levetiracetam treatment.MethodsThis was a cohort study based on pregnancies recorded by the Embryotox Center from 2000 to 2017. Outcomes of prospectively ascertained pregnancies with first trimester levetiracetam monotherapy (n = 221) were compared to pregnancies with lamotrigine monotherapy for epilepsy (n = 469). In addition, all pregnancies with levetiracetam (n = 364) exposure during the first trimester were analyzed in comparison to a nonexposed cohort (n = 729). Pregnancies with the most frequently used combination therapy comprising levetiracetam and lamotrigine (n = 80) were evaluated separately.ResultsThere was no significantly increased risk of major birth defects or of spontaneous abortions after first trimester exposure to levetiracetam. Birth weight of male neonates was significantly lower after levetiracetam monotherapy compared to lamotrigine monotherapy. Dual therapy with levetiracetam and lamotrigine resulted in a significantly increased risk of spontaneous abortion (adjusted hazard ratio = 3.01, 95% confidence interval [CI] = 1.43-6.33) and a nonsignificant effect estimate for major birth defects (7.7%, n = 5/65, adjusted odds ratio = 1.47, 95% CI = .48-4.47) compared to a nonexposed cohort.SignificanceOur study confirms the use of levetiracetam as a suitable antiepileptic drug in pregnancy. The lower birth weight of male neonates after maternal levetiracetam monotherapy and the unexpectedly high risk of spontaneous abortion and birth defects after dual therapy with levetiracetam and lamotrigine require further investigation.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 50 条
  • [1] Safety of Fluoroquinolone Treatment during First Trimester of Pregnancy: An Observational Cohort Study
    Padberg, Stephanie
    Wacker, Evelin
    Meister, Reinhard
    Panse, Mary
    Weber-Schoendorfer, Corinna
    Oppermann, Marc
    Schaefer, Christof
    BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2014, 100 (07) : 533 - 533
  • [2] Pregnancy outcome after first trimester exposure to bisoprolol: An observational cohort study
    Hoeltzenbein, Maria
    Fietz, Anne-Katrin
    Kayser, Angela
    Zinke, Sandra
    Meister, Reinhard
    Weber-Schoendorfer, Corinna
    Schaefer, Christof
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 231 - 232
  • [3] Pregnancy outcome after first trimester exposure to bisoprolol: an observational cohort study
    Hoeltzenbein, Maria
    Fietz, Anne-Katrin
    Kayser, Angela
    Zinke, Sandra
    Meister, Reinhard
    Weber-Schoendorfer, Corinna
    Schaefer, Christof
    JOURNAL OF HYPERTENSION, 2018, 36 (10) : 2109 - 2117
  • [4] Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study
    Hishinuma, Kayoko
    Yamane, Ritsuko
    Yokoo, Ikuko
    Arimoto, Takahide
    Takahashi, Kunihiko
    Goto, Mikako
    Saito, Yoshiyuki
    Nakajima, Ken
    Murashima, Atsuko
    Hayashi, Masahiro
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2021, 47 (05) : 1704 - 1710
  • [5] Observational Cohort Study of Pregnancy Outcome after First-Trimester Exposure to Fluoroquinolones
    Padberg, Stephanie
    Wacker, Evelin
    Meister, Reinhard
    Panse, Mary
    Weber-Schoendorfer, Corinna
    Oppermann, Marc
    Schaefer, Christof
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) : 4392 - 4398
  • [6] Exposure to cox-2 inhibitors (coxibs) during the first trimester and pregnancy outcome: a prospective observational cohort study
    Dathe, Katarina
    Padberg, Stephanie
    Hultzsch, Stefanie
    Koehler, Luisa-Maria
    Meixner, Katja
    Fietz, Anne-Katrin
    Tissen-Diabate, Tatjana
    Meister, Reinhard
    Schaefer, Christof
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (04) : 489 - 495
  • [7] Exposure to cox-2 inhibitors (coxibs) during the first trimester and pregnancy outcome: a prospective observational cohort study
    Katarina Dathe
    Stephanie Padberg
    Stefanie Hultzsch
    Luisa-Maria Köhler
    Katja Meixner
    Anne-Katrin Fietz
    Tatjana Tissen-Diabaté
    Reinhard Meister
    Christof Schaefer
    European Journal of Clinical Pharmacology, 2018, 74 : 489 - 495
  • [8] Pregnancy outcome after first-trimester exposure to fosfomycin for the treatment of urinary tract infection: an observational cohort study
    Wayan Philipps
    Anne-Katrin Fietz
    Katja Meixner
    Tobias Bluhmki
    Reinhard Meister
    Christof Schaefer
    Stephanie Padberg
    Infection, 2020, 48 : 57 - 64
  • [9] Pregnancy outcome after first-trimester exposure to fosfomycin for the treatment of urinary tract infection: an observational cohort study
    Philipps, Wayan
    Fietz, Anne-Katrin
    Meixner, Katja
    Bluhmki, Tobias
    Meister, Reinhard
    Schaefer, Christof
    Padberg, Stephanie
    INFECTION, 2020, 48 (01) : 57 - 64
  • [10] Yolk sac size & shape as predictors of first trimester pregnancy outcome: A prospective observational study
    Suguna, B.
    Sukanya, K.
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2019, 48 (03) : 159 - 164